ArticleJournal of cancer research and clinical oncology2020
Thoracic solitary fibrous tumors: an analysis of 70 patients who underwent surgical resection in a single institution.
Article in Journal of cancer research and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Recurrent Pleural Solitary Fibrous Tumor: A Case Report and Brief Literature Review.Reports (MDPI) · 2026Article
- Surgical approach to pleuropulmonary solitary fibrous tumour in the anterior mediastinum: case series at a third-level centre.Journal of cardiothoracic surgery · 2026Article
- Effectiveness of classification and scoring systems in solitary fibrous tumor prognosis prediction.Pakistan journal of medical sciences · 2026Article
- Article
- A Rare Metastatic Fibrous Tumor: Review of Literature With a Case Report.JTO clinical and research reports · 2025Article
- Clinical application of psychological intervention in perioperative patients with thoracic tumors.Pakistan journal of medical sciences · 2025Article
- Review
- Extra-meningeal solitary fibrous tumor: an evolving entity with chameleonic morphological diversity, a hallmark molecular alteration and unresolved issues in risk stratification assessment.Histology and histopathology · 2023Review
- Surgery for Solitary Fibrous Tumors of the Pleura: A Review of the Available Evidence.Cancers · 2023Review
- Histopathological features of giant mediastinal tumors-a literature review.Mediastinum (Hong Kong, China) · 2023Review
- Severe hypoglycemia and finger clubbing in a patient with a BRCA1 mutation in a solitary fibrous tumor: a case report.Annals of translational medicine · 2021Article
- Review
- Article
- Solitary fibrous tumor of the pleura: A giant finding, a benign entity?Respiratory medicine case reports · 2021Article
- Large Thoracic Solitary Fibrous Tumor: A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThoracic solitary fibrous tumors (TSFTs) are uncommon mesenchymal tumors. The data regarding surgical outcomes and prognostic factors are scarce. This retrospective paper is to analyze surgical outcomes, clinical characteristics and prognosis of TSFT.
methodsA single-center retrospective study of the data of 70 patients with TSFT who underwent surgical resection in our department between August 2008 and October 2014 was conducted.
resultsA total of 70 TSFTs (58 benign, 12 malignant) were included and all patients underwent complete surgical resection except one recurrent patient with initial treatment. TSFTs originated from the pleura (n = 43), lung (n = 9), mediastinum (n = 16), esophagus (n = 1) and diaphragm (n = 1), respectively. Mass excision was only performed in 29 patients, en bloc excision including surrounding structures was performed in 41 patients. During follow-up, no tumor recurrence occurred in benign TSFT patients. All recurrences occurred in 6 malignant patients, and 5 of them died because of local recurrence and distant metastasis. Median follow-up was 95 months (range, 3-133 months). The 5-year overall survival (OS) of TSFT patients was 94.3%. The 5-year relapse-free survival and OS of malignant TSFT patients were 58.3% and 66.7%, respectively.
conclusionThe gold standard of TSFT treatment is complete surgical resection. VATS is safe and reliable for treating selected TSFT patients. Aggressive surgical resection could be underwent in such patients of local recurrence or solitary metastatic tumor. A long-term follow-up is necessary due to the risk of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.